Revolution Medicines, Inc. revenue by year
Over the 8 fiscal years shown, revenue went from $20.16M (year ended Dec 31, 2018) to $0 (year ended Dec 31, 2025). The fastest growth was +148.2% in the year ended Dec 31, 2019; the weakest year was −100.0% (year ended Dec 31, 2024).
Annual revenue
| Fiscal year ended | Revenue (USD) | Change | XBRL concept | Reported in |
|---|---|---|---|---|
| Dec 31, 2025 | $0 | — | RevenueFromContractWithCustomerExcludingAssessedTax | 10-K filed Feb 25, 2026 |
| Dec 31, 2024 | $0 | −100.0% | RevenueFromContractWithCustomerExcludingAssessedTax | 10-K filed Feb 25, 2026 |
| Dec 31, 2023 | $11.58M | −67.3% | RevenueFromContractWithCustomerExcludingAssessedTax | 10-K filed Feb 25, 2026 |
| Dec 31, 2022 | $35.38M | +20.4% | RevenueFromContractWithCustomerExcludingAssessedTax | 10-K filed Feb 26, 2025 |
| Dec 31, 2021 | $29.39M | −31.6% | RevenueFromContractWithCustomerExcludingAssessedTax | 10-K filed Feb 26, 2024 |
| Dec 31, 2020 | $42.98M | −14.1% | RevenueFromContractWithCustomerExcludingAssessedTax | 10-K filed Feb 27, 2023 |
| Dec 31, 2019 | $50.04M | +148.2% | RevenueFromContractWithCustomerExcludingAssessedTax | 10-K filed Feb 28, 2022 |
| Dec 31, 2018 | $20.16M | — | RevenueFromContractWithCustomerExcludingAssessedTax | 10-K filed Mar 2, 2021 |
Quarterly revenue
Quarters reported in 10-Q filings. Fourth quarters are usually reported only inside the annual 10-K, so they are not listed separately here; we do not estimate them.
| Quarter | Revenue (USD) | vs same quarter a year earlier | Source |
|---|---|---|---|
| 3 months ended Sep 30, 2024 | $0 | — | 10-Q filed Nov 6, 2024 |
| 3 months ended Jun 30, 2024 | $0 | −100.0% | 10-Q filed Aug 7, 2024 |
| 3 months ended Mar 31, 2024 | $0 | −100.0% | 10-Q filed May 8, 2024 |
| 3 months ended Sep 30, 2023 | $0 | −100.0% | 10-Q filed Nov 6, 2024 |
| 3 months ended Jun 30, 2023 | $3.82M | −58.1% | 10-Q filed Aug 7, 2024 |
| 3 months ended Mar 31, 2023 | $7.01M | −7.4% | 10-Q filed May 8, 2024 |
| 3 months ended Sep 30, 2022 | $3.36M | +204.8% | 10-Q filed Nov 6, 2023 |
| 3 months ended Jun 30, 2022 | $9.12M | +4.8% | 10-Q filed Aug 8, 2023 |
Source: SEC EDGAR XBRL company facts for CIK 1628171 (raw data). Most recent filing in this dataset: 10-Q filed Aug 5, 2026. SEC data file dated Nov 3, 2026; page built Nov 5, 2026. Figures are as most recently reported, including restatements. How we select figures.